Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC)
-
Published:2018-08-08
Issue:
Volume:
Page:bcr-2018-225048
-
ISSN:1757-790X
-
Container-title:BMJ Case Reports
-
language:en
-
Short-container-title:BMJ Case Reports
Author:
Shrotriya Shiva,
Rai Manoj PORCID,
Alratroot Ahmad,
Sarzynski Erin
Reference24 articles.
1. Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab;Otsubo;Ann Oncol,2017
2. PD-1 as a potential target in cancer therapy;McDermott;Cancer Med,2013
3. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates;Brahmer;J Clin Oncol,2010
4. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial;Rizvi;Lancet Oncol,2015
5. Predisposing factors for adrenal insufficiency;Bornstein;N Engl J Med,2009
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献